Interview with Dr Paul Terasaki.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to Paul Terasaki.
Explore the source record for details and available documents.
Longer graft half-lives were associated with Caucasian race, living donors, younger donor age. The HLA-matching effect on graft half-life was only significant when comparing HLA-matched transplant recipients with recipients of HLA-mismatched transplants, but not significant between mismatched recipients with varying degrees of HLA mismatch. First transplant recipients maintained on newer post-1995 immunosuppressive drug therapies, including tacrolimus, MMF and steroids, Neoral, MMF and steroids or Neoral, azathioprine and steroids, always had longer graft half-lives than patients on pre-1995 CsA protocols. The difference in graft half-lives between new and old protocols reached statistical significance in some categories. Patients on triple therapies had consistently longer graft half-lives than those receiving double therapies.